Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Silvia Cona

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Critical Reviews in Oncology/Hematology|May 22, 2019
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesClaudio Vernieri, Monica Milano, Marta Brambilla, et al.
Tumori|May 5, 2026
The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumorsRaffaela D G Sartori, Davide Dalu, Davide De Francesco, et al.
The Pharmacogenomics Journal|March 2, 2021
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patientsSara Demurtas, Nicla La Verde, Selene Rota, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast UnitsNicla La Verde, Luisa Brogonzoli, Maria Silvia Cona, et al.
Cancers|February 17, 2019
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal AntibodiesMaria Silvia Cona, Mara Lecchi, Sara Cresta, et al.
Tumori|October 21, 2015
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?Diego Signorelli, Marianna Macerelli, Claudia Proto, et al.
Vaccines|June 27, 2024
Hospital-Based Influenza and Pneumococcal Vaccination for Cancer Patients on Active Treatment and Their Family Members during the COVID-19 Pandemic in Italy: A Single-Center ExperienceDavide Dalu, Anna Lisa Ridolfo, Lorenzo Ruggieri, et al.
International Journal of Cancer|December 15, 2023
Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patientsDavide Dalu, Maciej Tarkowski, Lorenzo Ruggieri, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Critical Reviews in Oncology/Hematology|May 22, 2019
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesClaudio Vernieri, Monica Milano, Marta Brambilla, et al.
Tumori|May 5, 2026
The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumorsRaffaela D G Sartori, Davide Dalu, Davide De Francesco, et al.
The Pharmacogenomics Journal|March 2, 2021
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patientsSara Demurtas, Nicla La Verde, Selene Rota, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast UnitsNicla La Verde, Luisa Brogonzoli, Maria Silvia Cona, et al.
Cancers|February 17, 2019
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal AntibodiesMaria Silvia Cona, Mara Lecchi, Sara Cresta, et al.
Tumori|October 21, 2015
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?Diego Signorelli, Marianna Macerelli, Claudia Proto, et al.
Vaccines|June 27, 2024
Hospital-Based Influenza and Pneumococcal Vaccination for Cancer Patients on Active Treatment and Their Family Members during the COVID-19 Pandemic in Italy: A Single-Center ExperienceDavide Dalu, Anna Lisa Ridolfo, Lorenzo Ruggieri, et al.
International Journal of Cancer|December 15, 2023
Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patientsDavide Dalu, Maciej Tarkowski, Lorenzo Ruggieri, et al.
Pageof 3